Plasma Therapy Accelerator – ‘SARS-Hunter” a New Solution for Better Antibody Therapy for All COVID-19Patients

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

How To Control a Radio Frequency (RF) Process

The radio frequency welding and manufacturing process uses electromagnetic energy and pressure to fuse and permanently bond vinyl, thermoplastic, and coated materials to produce a specific product - all according to customer requirements. Using this RF sealing process, a distinct, one-piece perpetual bond is formulated that is both solid and resistant to ripping or tearing. But how is this process controlled, and with what specific tools? Read on.

Genekam Biotechnology AG, Germany has developed a plasma therapy accelerator called SARS-Hunter, which gives the possibility to hospitals to isolate the antibodies from plasma to be given as therapy and increases the chances of success of treatment, while reducing the side effects of plasma therapy given today. Such antibodies (immunoglobulin subtype IgG) are usually rich in coronavirus (SARS-Cov-2) specific antibodies. This will solve the shortage problem also of therapy as millions of persons recovered from coronavirus 2020 can donate the plasma many times a year. SARS-Hunter is the quickest solution for the creation of effective antibodies therapy with low costs for all patients around the world.

Plasma from coronavirus recovered patients is being used as one of the successful therapeutic options to treat the corona virus-infected patients because it is rich in corona virus-specific antibodies. Plasma therapy may cause a number of side effects like allergic reactions, infections of other pathogens, acute lung injuries, red blood cell lysis (hemolysis) etc. To avoid the side effects and to give better results of plasma therapy, many big pharma companies are working to develop antibody therapy from such pooled plasma of recovered persons but such isolation can be done only at the industrial scale today as there is no machine available on the market, that one can do this at the hospital level. Genekam has developed such a small machine named SARS-Hunter, which can isolate such antibodies at the hospital level and these antibodies can be administered to the patient after running some simple safety tests particularly bacterial contamination. Another advantage is that cost of the antibody therapy can be reduced and the number of patients becoming this therapy will be increased as millions of recovered persons can donate their plasma multiple times. Plasma donors with high-quality neutralizing corona specific antibodies will help to create effective therapeutic doses, which can be given to more patients instead of giving whole plasma to one patient. This machine is very simple to operate and isolate antibodies within 1 hour. It weighs around 400 gm (very light). SARS-hunter can have a very strong impact on the antibody therapy and should make available antibody therapy to a large population. SARS-Hunter including reagents costs US$ 1499,-.



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.